Atossa Therapeutics granted new patent for endoxifen

Atossa Therapeutics announces that the United States Patent and Trademark Office, USPTO, has granted a new patent directed to (Z)-endoxifen encapsulated in an enteric capsule. This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen. A short ‘explainer’ video about the new patent can be found here: Patent Update – Video Explainer. "We are very pleased with the scope and breadth of this new key patent," said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. "It ensures that in the U.S., Atossa will have the only (Z)-endoxifen treatment delivered orally with an enteric capsule, which we believe is the optimal way to deliver the drug. This new patent, further strengthens our intellectual property estate and should create long-term stockholder value." Atossa is developing its proprietary (Z)-endoxifen in both the breast cancer treatment and prevention settings. Phase 2 trials are ongoing with the goal of changing the treatment paradigm for patients who are not benefiting from currently approved drugs and helping reduce the incidence of breast cancer.